Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 15/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404874 | 0.95 | LSS (0.44) | LSSMEN1KMT2AMAPT | |
| SCHEMBL6399632 | 0.94 | LSS (0.45) | LSSMEN1KMT2A | |
| SCHEMBL5637168 | 0.89 | LSS (0.41) | LSSNPC1POLBHTTRAB9A | |
| SCHEMBL6398746 | 0.88 | NPC1 (0.42) | LSSNPC1POLBHTTRAB9A | |
| SCHEMBL5639493 | 0.88 | LSS (0.44) | LSSPOLBSMN1; SMN2MAPT | |
| SCHEMBL5637280 | 0.87 | LSS (0.47) | LSSMEN1KMT2A | |
| SCHEMBL5971331 | 0.85 | TP53 (0.39) | POLBHTTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5639431 | 0.85 | LSS (0.44) | LSSMEN1KMT2A | |
| SCHEMBL6404546 | 0.84 | LSS (0.40) | LSSMEN1KMT2AMAPT | |
| SCHEMBL5637376 | 0.83 | LSS (0.48) | LSSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | claimed |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
| US-20050020624-A1 | Dihydroindole and tetrahydroquinoline derivatives | AEBI JOHANNES (CH) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020624-A1 | Dihydroindole and tetrahydroquinoline derivatives | CYP46A1, LSS, CYP51A1 | LSS 2/4885NPC1 171/4885POLB 4298/4885 |
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | HAVCR2, MAVS, ZC3HAV1 | LSS 65/4885NPC1 149/4885POLB 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.